News | Cath Lab | June 20, 2019

New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium

Major cardiovascular conferences will collaborate on creating educational content for each other

New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium

June 20, 2019 – VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter Cardiovascular Therapeutics (TCT) and the VEITHsymposium. TCT is the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine. VEITHsymposium is the leading global conference covering all aspects of vascular medicine, vascular surgery and endovascular intervention.

As part of this alliance, the two organizations will closely collaborate on creating educational content for physicians, surgeons and other healthcare professionals. The VEITHsymposium leadership will be actively involved in developing the endovascular program for TCT 2019, taking place Sept. 25-29 in San Francisco. The VEITHsymposium group will also plan dedicated critical limb ischemia and aortic sessions at TCT 2019. Similarly, CRF will actively participate in the development of a two-day hands-on training pavilion and other interventional sessions at this year’s VEITHsymposium, which will take place Nov. 19-23 in New York City.

“We are pleased to be partnering with such an esteemed educational conference as the VEITHsymposium,” said Juan F. Granada, M.D., president and CEO of CRF. “Over the last 45 years, they have had a remarkable influence on medical education and innovation in the field, which has had a tremendous impact on patient care.”

Watch the VIDEO: Cath Lab of the Future Cardiovascular Technologies to Watch, an interview with Granada at TCT 2017.

“This alliance between two leading continuing medical educational meetings has as its goal the provision of the best, most up-to-date information possible to all those specializing in the care of non-cardiac vascular disease patients,” said Frank J. Veith, chairman of VEITHsymposium.  “This unique alliance will lead to better, more appropriate care for the increasing number of vascular disease patients around the world, while recognizing the reality that many specialties are involved in providing this care.”

“Vascular disease is a leading cause of death and disability,” said Sahil A. Parikh, M.D., director, endovascular services at the Center for Interventional Vascular Therapy at New York-Presbyterian/ Columbia University Irving Medical Center and director of the endovascular program of TCT. “It’s critically important for physicians and other healthcare professionals to be educated and trained on the latest endovascular treatments. This alliance will help improve the survival and quality of life for patients with vascular disease by emphasizing multidisciplinary care of vascular patients.”

"Limitless opportunities for improved care of vascular patients is the primary goal of this new and exciting alliance between two well established giants in the area of education,” said Enrico Ascher, M.D., co-chairman of VEITHsymposium. “Providing a balanced, progressive environment where all vascular care professionals can learn from each other is one other motivating factor that led to this arrangement. I’m certain that this new concept of working together for the benefit of our patients and for the advancement of science will succeed big time!”

“For decades, TCT has been the foremost conference for cardiovascular interventional therapy and the VEITHsymposium has been the leading meeting for non-cardiac vascular medicine and surgery,” said Kenneth Ouriel, M.D., MBA, co-chairman of VEITHsymposium. “The new alliance provides the opportunity to expand non-cardiac vascular educational offerings at TCT and interventional cardiology opportunities at the VEITHsymposium. The end result will be the most comprehensive cardiovascular conference in the world today.”

For more information: www.crf.org, www.veithsymposium.org

Related Content

Gallery | Cath Lab | October 31, 2019
This is a photo essay of the interventional cardiology and structural heart technologies on the expo floor and discus
The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

Technology | Cath Lab | October 28, 2019
Office based labs (OBLs) and ambulatory surgery centers (ASCs) require a fresh perspective from imaging vendors.
Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

News | Cath Lab | October 28, 2019
October 28, 2019 — Leaders within University Hospitals and the Harrington Heart and Vascular Institute had a vision t
OmniVision Announces Guinness World Record for Smallest Image Sensor

OmniVision's OVM6948 CameraCubeChip, a fully packaged, wafer-level camera module measuring 0.65mm x 0.65mm x 1.158mm, built on OmniVision's OV6948, winner of the Guinness World Record for “The Smallest Image Sensor Commercially Available.”

News | Cath Lab | October 22, 2019
October 22, 2019 — OmniVision Technologies Inc.
People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. 

Feature | Cath Lab | October 03, 2019
October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with pe
Two Stents Implanted in Democratic Presidential Candidate Bernie Sanders, suffers chest pain
News | Cath Lab | October 02, 2019 | Dave Fornell, Editor
October 2, 2019 — Democratic presidential candidate Sen.
Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival
News | Cath Lab | September 25, 2019
Ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting stents in randomized...
Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
Overlay Init